Abstract
BackgroundLung adenocarcinoma (LUAD) is the most common type of lung cancer and is a severe threat to human health. Although many therapies have been applied to LUAD, the long-term survival rate of patients remains unsatisfactory. We aim to find reliable immune microenvironment-related lncRNA biomarkers to improve LUAD prognosis.MethodsESTIMATE analysis was performed to evaluate the degree of immune infiltration of each patient in TAGA LUAD cohort. Correlation analysis was used to identify the immune microenvironment-related lncRNAs. Univariate cox regression analysis, LASSO analysis, and Kaplan Meier analysis were used to construct and validate the prognostic model based on microenvironment-related lncRNAs.ResultsWe obtained 1,178 immune microenvironment-related lncRNAs after correlation analysis. One hundred and eighty of them are independent prognostic lncRNAs. Sixteen key lncRNAs were selected by LASSO method. This lncRNA-based model successfully predicted patients’ prognosis in validation cohort, and the risk score was related to pathological stage. Besides, we also found that TP53 had the highest frequency mutation in LUAD, and the mutation of TP53 in the high-risk group, which was identified by our survival model, has a poor prognosis. lncRNA-mRNA co-expression network further suggested that these lncRNAs play a vital role in the prognosis of LUAD.ConclusionHere, we filtered 16 key lncRNAs, which could predict the survival of LUAD and may be potential biomarkers and therapeutic targets.
Highlights
The incidence of lung cancer exceeds 2 million each year, of which approximately 1.8 million die, making it the leading cause of cancer-related deaths worldwide [1]
We investigated relationship between the mutation of TP53 and overall survival (OS) in the high- and low-risk groups and found the mutation of TP53 indicated poor prognosis in the high-risk group (Figure 6C; P = 3.1E-02), but there was no distinction in the low-risk group (Figure 6D; P = 9.8E-01), and there has a trend but no statistical significance in whole TCGA Lung adenocarcinoma (LUAD) cohort (Figure 6E; P = 6.3E-02)
We found that three lncRNAs were related to prognosis in top 5 degrees lncRNAs in TCGA LUAD cohort
Summary
The incidence of lung cancer exceeds 2 million each year, of which approximately 1.8 million die, making it the leading cause of cancer-related deaths worldwide [1]. Numerous therapeutic clinical trials in NSCLC have shown that LUAD patients showed different responses compared with LUSC [3, 6]. This suggests that LUAD and LUSC are different at pathological and molecular levels. LUAD morphologic types include glandular alveolar, papillary, solid, micropapillary, and invasive mucinous types [7] It is more common in women than in men and is more likely to occur in younger people and to present in a more advanced stage [8]. Lung adenocarcinoma (LUAD) is the most common type of lung cancer and is a severe threat to human health. We aim to find reliable immune microenvironment-related lncRNA biomarkers to improve LUAD prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
